3 oktober 2018 Sweden
Intralymphatic immunotherapy with the diabetes vaccine Diamyd® explained
Video showing the novel antigen-specific immunotherapy Diamyd®, for the treatment of autoimmune diabetes.
Diamyd® is based on the protein GAD65, an activator of the immune system involved in the pathology of autoimmune diabetes. By preventing the autoimmune destruction of insulin producing cells, Diamyd® has the potential to significantly reduce the complications of type 1 diabetes and LADA. Diamyd® is in Phase II clinical development.
Information som presenteras här är inte pressmeddelanden och kan innehålla utdrag ur och länkar till externt publicerat innehåll. Diamyd Medical ansvarar inte för externt publicerat innehåll.